Frontiers
Browse

Data_Sheet_1_A Clinical Rationale for Assessing the Impact of Childhood Sexual Abuse on Adjunctive Subcutaneous Esketamine for Treatment-Resistant Depression.docx

Download (848.38 kB)
dataset
posted on 2021-08-17, 04:17 authored by Eduardo Jorge Muniz Magalhães, Luciana Maria Sarin, Lorena Catarina Del Sant, Ana Cecília Lucchese, Carolina Nakahira, Marco Aurélio Tuena, Camila Brito Puertas, Victor Augusto Rodovalho Fava, Rodrigo Simonini Delfino, Juliana Surjan, Matheus Souza Steglich, Matheus Ghossain Barbosa, Guilherme Abdo, José Alberto Del Porto, Charles B. Nemeroff, Hugo Cogo-Moreira, Acioly Luiz Tavares Lacerda, Andrea Feijo Mello

Background: A history of child sexual abuse (CSA) is related to higher suicide rates and poor treatment outcomes in depressed adult patients. Twenty years after the first study investigating the effects of ketamine/esketamine on depression and suicide, there is a lack of data on the CSA effects on this emerging treatment. Here, we assess the impact of CSA on adjunctive subcutaneous (SC) esketamine for treatment-resistant depression (TRD).

Methods: A directed acyclic graphic (DAG) was designed to identify clinical confounders between CSA and esketamine predictors of response. The confounders were applied in a statistical model to predict depression symptom trajectory in a sample of 67 TRD outpatients.

Results: The patient sample had a relatively high prevalence rate of CSA (35.82%). Positive family history of first-degree relatives with alcohol use disorder and sex were clinical mediators of the effects of esketamine in a CSA adult population. Overall, the presence of at least one CSA event was unrelated to esketamine symptom reduction.

Conclusions: Unlike responses to conventional antidepressants and psychotherapy, CSA does not appear to predict poor response to esketamine.

History

Usage metrics

    Frontiers in Psychiatry

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC